Lung Cancer, Behavior
Conditions
Keywords
screening adherence
Brief summary
The research study aims to create a program for lung cancer screening attendance
Detailed description
The overall objective of this project is to demonstrate the impact of a community support program (CSP) on improving adherence to LCS follow-up guidelines in an urban environment. The project aims to collaborate with community partners to develop an infrastructure and iterative process to provide social support to community members that facilitates obtaining their follow-up LDCT for LCS. It utilizes novel population level data that includes geospatial analysis of neighborhood-level data of patients residing in Philadelphia who have received a LDCT for LCS. This allows for targeted community level interventions and the ability to evaluate impact on a population level. A Community Support Program Representative will reach out to eligible patients via telephone. The CSP Representative and Patient Navigator will communicate with consented patient directly, assist with travel and the appointment. The PN will log the date of the appointment, zip code of the patient and the adherence (or lack of) of the appointment completion. We will utilize Lyft transportation vouchers to provide rides to participants from their home location in West Philadelphia to and from the Penn Medicine downtown hospital locations on the day of their LDCT.
Interventions
BEHAVIORALTransportation
Eligible patients are contacted and offered free transportation to and from their upcoming appointment.
Sponsors
Abramson Cancer Center at Penn Medicine
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes
Inclusion criteria
* Upcoming or missed follow-up LDCT (low dose CT) * West Philadelphia resident * Between 18-89 years' old
Exclusion criteria
* No upcoming LDCT * Lives outside West Philadelphia * Outside age range
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants | 12 months | The Primary Outcome measures the rate of appointment attendance across three groups: West Philadelphia CSP Participants (eligible West Philadelphia residents who opted into the CSP), West Philadelphia Non CSP Participants (eligible West Philadelphia residents who did not opt into the CSP), and Southwest Philadelphia Residents (patients who did not receive an option to participate in the CSP). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of CSP Enrollment | 12 months | The Secondary outcome is a measurement of the percentage of eligible participants (West Philadelphia residents) who chose to opt into the CSP (as opposed to eligible participants who did not). |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| West Philadelphia CSP Participants For eligible residents of West Philadelphia, patients are contacted by Community Support Program Representative and offered free Lyft transportation to and from appointment. If patient has other questions about their upcoming appointment (location, time, etc.), Patient Navigator assists in answering questions. This group opted into the CSP. | 26 |
| West Philadelphia Non CSP Participants For eligible residents of West Philadelphia, patients are contacted by Community Support Program Representative and offered free Lyft transportation to and from appointment. If patient has other questions about their upcoming appointment (location, time, etc.), Patient Navigator assists in answering questions. This group did not opt into the CSP. | 165 |
| Southwest Philadelphia Residents For patients outside West Philadelphia, no contact is made and no free transportation is provided. Research coordinator logs their appointment attendance after the appointment date in question. | 51 |
| Total | 242 |
Baseline characteristics
| Characteristic | West Philadelphia CSP Participants | Total | Southwest Philadelphia Residents | West Philadelphia Non CSP Participants |
|---|---|---|---|---|
| Age, Customized Age 18-89 | 26 participants | 242 participants | 51 participants | 165 participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 26 Participants | 239 Participants | 51 Participants | 162 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 2 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 26 Participants | 223 Participants | 48 Participants | 149 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 0 Participants | 14 Participants | 3 Participants | 11 Participants |
| Region of Enrollment United States | 26 participants | 242 participants | 51 participants | 165 participants |
| Scheduled Lung Cancer Screening | 26 participants | 242 participants | 51 participants | 165 participants |
| Sex: Female, Male Female | 18 Participants | 144 Participants | 28 Participants | 98 Participants |
| Sex: Female, Male Male | 8 Participants | 98 Participants | 23 Participants | 67 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 0 | 0 / 0 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants
The Primary Outcome measures the rate of appointment attendance across three groups: West Philadelphia CSP Participants (eligible West Philadelphia residents who opted into the CSP), West Philadelphia Non CSP Participants (eligible West Philadelphia residents who did not opt into the CSP), and Southwest Philadelphia Residents (patients who did not receive an option to participate in the CSP).
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| West Philadelphia CSP Participants | Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants | 88 % of lcs appointment attendance |
| West Philadelphia Non CSP Participants | Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants | 68 % of lcs appointment attendance |
| Southwest Philadelphia Residents | Percentage of Scheduled Lung Cancer Screening Appointments Attended by Participants | 64 % of lcs appointment attendance |
Secondary
Percentage of CSP Enrollment
The Secondary outcome is a measurement of the percentage of eligible participants (West Philadelphia residents) who chose to opt into the CSP (as opposed to eligible participants who did not).
Time frame: 12 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| West Philadelphia CSP Participants | Percentage of CSP Enrollment | 14 percentage of participants |